ELX-02 Lowers Sweat Chloride in Patients With G542X Mutation, Trials Find

ELX-02 Lowers Sweat Chloride in Patients With G542X Mutation, Trials Find

312411

ELX-02 Lowers Sweat Chloride in Patients With G542X Mutation, Trials Find

Eloxx Pharmaceuticals’ experimental therapy ELX-02 was generally safe and resulted in a significant reduction in sweat chloride levels — a biomarker of cystic fibrosis (CF) — in patients carrying the most common CF-causing nonsense mutation, according to top-line data from a Phase 2 clinical program. While the short duration of treatment (one week) did not allow significant changes in lung function to be detected, findings suggest that the therapy improved the activity of CFTR, the…

You must be logged in to read/download the full post.